Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST segment elevation myocardial infarction: A pilot study.

Zhu J, Song J, Yu L, Zheng H, Zhou B, Weng S, Fu G

Cytotherapy7 Jun 2016Cited by 24 (Europe PMC)

PMID27288307DOI10.1016/j.jcyt.2016.05.006PepBankPUB-27288307

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

01HumanNot a test of Thymosin beta-4 (human) aloneRandomized controlled trialEfficacy outcome
In patients with acute STEMI, the 6-min walking distance rose 37.5 m more with Tβ4-pre-treated EPC transplantation than with EPC transplantation alone.
In plain wordsIn heart attack patients, cells pre-treated with Tβ4 in the lab gave 37.5 m more walking distance than untreated cells.
Peptide
Thymosin beta-4 (human)
Outcome
Increase6-min walking distance difference between groups
Study
n = 10
Comparator
EPC transplantation without Tβ4 pre-treatment
Outcome group
Exercise and physical function · Cardiovascular
Measurements
difference in 6-min walking distance
37.5 m
experimental vs control group
Source sentences
Summary
After 6 months of follow-up, the average 6-min walking distance was increased by 38.2 m (from 263 ± 42 m to 302 ± 34 m) in the control group and 75.7 m (from 264 ± 42 m to 340 ± 44 m) in the experimental group; the average difference of the 6-min walking distance was 37.5 m (95% confidence interval…
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients with STEMI were included; they were randomized to 2 groups: EPC transplantation group (control group; n = 5) and Tβ4-pre-treated EPC transplantation group (experimental group; n = 5).
Summary · context
EPCs were pre-treated with Tβ4 24 hours before transplantation in experimental group.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2728830701
02HumanNot a test of Thymosin beta-4 (human) aloneRandomized controlled trialEfficacy outcome
In patients with acute STEMI, cardiac function improved more with Tβ4-pre-treated EPC transplantation than with EPC transplantation alone.
In plain wordsIn heart attack patients, cells pre-treated with Tβ4 in the lab improved heart function more than untreated cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseCardiac function
Study
n = 10
Comparator
EPC transplantation without Tβ4 pre-treatment
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
In addition, the cardiac function in the experimental group was more significantly improved than that of the control group.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients with STEMI were included; they were randomized to 2 groups: EPC transplantation group (control group; n = 5) and Tβ4-pre-treated EPC transplantation group (experimental group; n = 5).
Summary · context
EPCs were pre-treated with Tβ4 24 hours before transplantation in experimental group.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2728830703
03HumanNot a test of Thymosin beta-4 (human) aloneRandomized controlled trialSafety outcome
In patients with acute STEMI, no severe procedure-related complications occurred in either group during follow-up.
In plain wordsIn heart attack patients, no severe procedure complications occurred in either the pre-treated cell group or the untreated cell group.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeSevere procedure-related complications
Study
n = 10
Comparator
EPC transplantation without Tβ4 pre-treatment
Outcome group
Adverse events · Cardiovascular
Source sentences
Summary
There were no severe complications related to the procedure in either group during the follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients with STEMI were included; they were randomized to 2 groups: EPC transplantation group (control group; n = 5) and Tβ4-pre-treated EPC transplantation group (experimental group; n = 5).
Summary · context
EPCs were pre-treated with Tβ4 24 hours before transplantation in experimental group.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2728830704
04HumanNot a test of Thymosin beta-4 (human) aloneRandomized controlled trialEfficacy outcome
In patients with acute STEMI, the 6-min walking distance in the Tβ4-pre-treated EPC group increased by 75.7 m after 6 months.
In plain wordsIn heart attack patients given cells pre-treated with Tβ4 in the lab, walking distance rose by 75.7 m over 6 months.
Peptide
Thymosin beta-4 (human)
Outcome
Increase6-min walking distance change in Tβ4-pre-treated EPC group
Study
n = 5
Outcome group
Exercise and physical function · Cardiovascular
Measurements
change in 6-min walking distance
75.7 m
experimental group
Source sentences
Summary
After 6 months of follow-up, the average 6-min walking distance was increased by 38.2 m (from 263 ± 42 m to 302 ± 34 m) in the control group and 75.7 m (from 264 ± 42 m to 340 ± 44 m) in the experimental group; the average difference of the 6-min walking distance was 37.5 m (95% confidence interval…
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients with STEMI were included; they were randomized to 2 groups: EPC transplantation group (control group; n = 5) and Tβ4-pre-treated EPC transplantation group (experimental group; n = 5).
Summary · context
EPCs were pre-treated with Tβ4 24 hours before transplantation in experimental group.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2728830702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.